A GWAS meta‑analysis of more than 640,000 individuals identified a rare noncoding variant, rs17834140‑T, that substantially lowers the risk of clonal hematopoiesis of indeterminate potential (CHIP) and reduces subsequent blood cancer risk. Published in Science, the study links the protective effect to weakened activity of the RNA binding protein MSI2 by disrupting a GATA‑2 transcription factor binding site; gene‑edited human hematopoietic stem cells recapitulated the restrained clonal growth. Authors proposed MSI2 as a potential therapeutic axis to limit clonal expansion and age‑related hematologic malignancies.